Volker Brinkmann / Max Planck Institute for Infection BiologyDutch inflammation specialist Citryll BV has raised €85m to push clininal testing of its lead candidate, CIT-013, a bifunctional antibody that prevents the release of neutrophil extracellular traps (NETs) from neutrophil granulocytes into the cytoplasm, thus blocking inflammatory and autoimmune diseases at its very roots.
ADVERTISEMENT